Spots Global Cancer Trial Database for puma
Every month we try and update this database with for puma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | NCT01664000 | Solid Tumors | thioureidobutyr... | 18 Years - | Cellceutix Corporation | |
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | NCT01827267 | HER2-mutant Non... | neratinib temsirolimus | 18 Years - | Puma Biotechnology, Inc. | |
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre |